Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Cross NCP. et al, (2018), British journal of haematology
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W. et al, (2018), J Clin Oncol, 36, 2395 - 2404
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC. et al, (2018), The Lancet. Oncology, 19, 1027 - 1039
Single Cell Analysis Resolves Genetic and Transcriptional Heterogeneity in Myeloproliferative Neoplasms
Rodriguez-Meira A. et al, (2018), Experimental Hematology, 64
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
Lipplaa A. et al, (2018), British Journal of Cancer
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology
Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer
Lord SR. et al, (2018), Cell Metabolism
A decision support system for the treatment of esophageal cancer
Mistry H. et al, (2018), CANCER RESEARCH, 78
INCIDENCE AND MANAGEMENT OF IMMUNOTHERAPY-INDUCED COLITIS IN A TERTIARY IBD CENTRE - CLINICAL PRACTICE DATA
Gupta T. et al, (2018), GUT, 67, A186 - A187
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2018), BMC Health Serv Res, 18
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).
Chen RW. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.
Azaro A. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.
Straus DJ. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.
Shoushtari AN. et al, (2018), Journal of Clinical Oncology, 36, 9593 - 9593
Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells.
Neo WH. et al, (2018), Blood, 131, 2223 - 2234
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P. et al, (2018), J Clin Oncol, 36, 1428 - 1439
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
MacGregor TP. et al, (2018), Scientific reports, 8, 7265 - 7265
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Gleeson M. et al, (2018), Lancet Haematol, 5, e190 - e200
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D. et al, (2018), J Clin Oncol, 36, 1291 - 1299